Omeed Moaven, MD
Dr. Omeed Moaven is a surgical oncologist and Assistant Professor of Clinical Surgery at LSU Health New Orleans and LSU University Medical Center in New Orleans, Louisiana. His practice is focused on hepatobiliary, pancreatic, and metastatic malignancies including malignant peritoneal mesothelioma, which he treats using a complex surgical procedure that combines cytoreductive surgery with hyperthermic intraperitoneal chemotherapy[1].
Dr. Moaven is dedicated to both clinical care and academic research. He is also passionate about training the next generation of surgeons, and particularly those who are interested in pursuing a similar path to his own.
Education and Career
Dr. Moaven earned his medical degree at the Mashhad University of Medical Sciences in Mashhad, Iran. He completed an internship and residency at Massachusetts General Hospital and an additional residency at the University of Alabama, Birmingham. He also completed post-doctoral fellowships at the Hodin Lab in the Department of Surgery at Massachusetts General Hospital/Harvard Medical School, the Tanabe Lab in the Division of Surgical Oncology, the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, and clinical fellowships in Complex General Surgical Oncology at Wake Forest University.[1]
Professional Memberships and Activities
Dr. Moaven is actively involved in numerous committees and professional medical societies. He is a member of LSU-LCMC Cancer Center’s Clinical Trial Protocol Review and Monitoring Committee and is the Chair of the Clinical Research Oversight and Prioritization Committee. Additionally, he is on the University Medical Center’s Cancer Surgery Committee and Cancer Committee.[1]
Outside of the hospital and medical school, he is a member of:[1]
- American Association for Cancer Research
- American College of Surgeons
- American Society of Clinical Oncology
- Society of Surgical Oncology
- Association of Academic Surgery
- Americas Hepatopancreaticobiliary Association
- Pancreas Club
- Alliance for Clinical Trials
- Society of Immunotherapy for Cancer
Research
Dr. Moaven leads a translational research program focused on investigating oncolytic virotherapy to improve response to immunotherapy for pancreatic cancer. His lab has designed novel oncolytic viruses being investigated to target and remodel pancreatic cancer tumor microenvironment and improve immune response against pancreatic cancer. He is interested in program development and has established the EMPOWER Program at the University Medical Center, which is “Evaluation, Multimodality Prehabilitation, and Oncology Support: a Well-being Enhancement Resource.” EMPOWER program is a multidisciplinary prehabilitation program focused on improving patients’ performance, physical, and nutritional status and providing psychosocial support for patients undergoing neoadjuvant treatment for HPB/GI malignancies, aiming to improve the outcomes of oncologic surgical resection. He is leading a team that is prospectively investigating the outcomes of this prehabilitation program. His clinical research also includes investigating disparities in HPB/GI malignancies.[1]
His recent publications include:[1]
Solsky I, Moaven O, Valenzuela CD, Lundy M, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha C, Zarandi NP, Dourado J, Russell G, Levine EA, Votanopoulos KI, Shen P. Survival Outcomes of Optimally Treated Colorectal Metastases: The Importance of R0 Status in Surgical Treatment of Hepatic and Peritoneal Surface Disease. Ann Surg Oncol. 2023 Jul;30(7):4264-4273. doi: 10.1245/s10434-023-13174-3. Epub 2023 Feb 8. PubMed PMID: 36754944.
Mangieri CW, Strode MA, Moaven O, Valenzuela CD, Erali RA, Howerton R, Shen P, Clark CJ. Risk factors and outcomes for cholangitis after hepatic resection. Langenbecks Arch Surg. 2023 Jun 17;408(1):236. doi: 10.1007/s00423-023-02769-9. PubMed PMID: 37329363.
Valenzuela CD, Moaven O, Solsky IB, Stauffer JA, Del Piccolo NR, Cheung T, Corvera CU, Wisneski AD, Cha CH, Pourhabibi Zarandi N, Dourado J, Perry KC, Russell G, Shen P. Conditional Survival After Hepatectomy for Colorectal Liver Metastasis: Results from the Colorectal Liver Operative Metastasis International Collaborative (COLOMIC). Ann Surg Oncol. 2023 Jun;30(6):3413-3422. doi: 10.1245/s10434-023-13189-w. Epub 2023 Mar 1. PubMed PMID: 36859704.
Moaven O, Tavolara TE, Valenzuela CD, Cheung TT, Corvera CU, Cha CH, Stauffer JA, Niazi MKK, Gurcan MN, Shen P. Machine Learning Models for Predicting the Outcomes of Surgical Treatment of Colorectal Liver Metastases. J Am Coll Surg. 2023 Apr 1;236(4):884-893. doi: 10.1097/XCS.0000000000000573. Epub 2023 Jan 19. PubMed PMID: 36727981.
Valenzuela CD, Moaven O, Gawdi R, Stauffer JA, Del Piccolo NR, Cheung TT, Corvera CU, Wisneski AD, Cha C, Pourhabibi Zarandi N, Dourado J, Perry KC, Russell G, Shen P. Outcomes after repeat hepatectomy for colorectal liver metastases from the colorectal liver operative metastasis international collaborative (COLOMIC). J Surg Oncol. 2022 Dec;126(7):1242-1252. doi: 10.1002/jso.27056. Epub 2022 Aug 15. PubMed PMID: 35969175; PubMed Central PMCID: PMC9613625.
Book Chapters:[1]
1. Moaven O. Intestinal Alkaline Phosphatase. In: Schwab M. (Ed.) Encyclopedia of Cancer: SpringerReference (www.springerreference.com). Springer-Verlag Berlin Heidelberg, 2015. DOI: 10.1007/978-3-642-27841-9_7126-15
2. Moaven O. Chen H. Medullary Thyroid Cancer. In: Dimick JB, Upchurch GR, Sonnenday CJ, Kao L. Clinical Scenarios in Surgeries: Decision Making and Operative Technique 2018 2nd edition. Omeed Moaven, MD 10
3. Moaven O, Contreras CC. Nature and Clinical Impact of Physiologic Changes Associated with Aging. In: Ashley SW. (Ed) In: Scientific American Surgery. 2018
4. Moaven O, Shen P, Levine EA, Votanopoulos KI. Current Evidence for the Management of Appendiceal Cancer with Peritoneal Surface Dissemination. Current problems in surgery 2020 doi:https://doi.org/10.1016/j.cpsurg.2020.100860
